To corroborate the potential of combination therapy in enhancing the tumor immune microenvironment, we employed flow cytometry for the detection of MDSCs (CD11b+ Gr-1+) infiltration within tumor tissues after 2 weeks treatment (Figures 5E, G, Supplementary Figure S8). Here, ITGAM is linked to neoplasm.